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Sir, 
I would like to bring your attention to a number of significant
errors in the above article which are extremely misleading, both in
terms of the clinical effectiveness and cost of the drugs evaluated.
For ease of reference I have listed where mistakes have been made
below: 
Table 1 Gemcitabine is also licensed for treatment of advanced
bladder cancer (muscle invasive Stage IV tumours with and
without metastases) in combination with cisplatinum. 
Paclitaxel is also licensed for the treatment of non small cell
lung cancer (NSCLC) 
Docetaxel is also licensed for the treatment of second line
NSCLC. 
The table, as it stands, is incomplete and misleading about the
licensed indications of these drugs. 
Table 1 The costs have been calculated on a ‘per cycle basis’. 
The costs of Gemcitabine per cycle is listed as £1030, and the cost
of Vinorelbine £175 – suggesting that Gemcitabine is approximately
6 times as expensive as Vinorelbine on a per cycle basis. The actual
costs are in fact similar (for a cycle or course of treatment) and the
table should therefore be corrected, so that 3 infusions of
Gemcitabine are not compared to one infusion of Vinorelbine. 
Table 3 The effectiveness of new treatment scale claims that
Vinorelbine/Cisplatin has a 3–6 month survival advantage over
Cisplatin in first line NSCLC, with strength of evidence alpha +. It
would be interesting to see on what data this claim is based. There is
no mention of the comparable trial of Gemcitabine/Cisplatin vs
Cisplatin – in the first line setting, which should be included here as it
showed a significant survival advantage (P = 0.004). Added to which
39% one year survival for the Gemcitabine/Cisplatin combination is
not surpassed by any similar Vinorelbine/Cisplatin combinations. 
It is also worth noting that in the only comparative trial where
Gemcitabine/Cisplatin and Vinorelbine/Cisplatin have been
compared (although admitedly not compared head to head) the
Gemcitabine/Cisplatin arm appeared extremely favourable to 
the Vinorelbine/Cisplatin arm in terms of survival, where the
Vinorelbine/Cisplatin arm was dropped at the interim analysis
stage due to inferior efficacy. 
Gemcitabine has no licence for the second-line treatment of
NSCLC and this statement is therefore incorrect and should be
removed, added to which there are no randomized data to support
this effectiveness claim in the second line setting. 
There are a number of tumour types where new treatments are
available that have not been listed in the table such as pancreatic
cancer, bladder cancer and glioblastoma multiforme. 
These are the major inaccuracies. 
It is also worth commenting that whilst survival is often consid-
ered the most important endpoint in clinical trials, tumour types
which are notoriously chemoresistant such as NSCLC, pancreatic
cancer, and renal cancer can be discriminated against by using a
generic ranking scale which compares relatively chemosensitive
disease such as ovarian cancer, with those where survival benefits
may be hard to show, but where improvement in quality of life
may be just as important. 
Dr Nicholas Botwood 
Research Physician Lilly Oncology 
ENC – SPC, 
Sandler, 
Comelia 
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Sir, 
Neither the use of gemcitabine in bladder cancer nor the use of
docetaxel in non small cell lung cancer NSCLC were licensed
for these indications in the UK at the time of writing or
preparing the manuscript. More importantly there had been no
demand from clinicians locally to use these products in these
indications. This also explains the omission of paclitaxel treat-
ment for NSCLC (licensed Nov 1998). It should be noted that in
our next meeting to appraise new anticancer agents we will be
considering the use of gemcitabine plus cisplatin in bladder
cancer. 
Cost per cycle 
Price does not affect a rating a drug receives. We would concede
that if used as a price comparison for different treatments Table 1
could be misleading. However it would be extremely unwise to do
this for several reasons including the variability in pricing between
institutions and over time depending on the level of discount and
the variant regimens of the different drugs used. 
There is a good reason why the vinorelbine price per week is
given. At the time of writing (and currently) the dosage schedules
used for this drug are more variable than most and include once
weekly continuous treatment – with such a treatment, the appro-
priate cycle length is very hard to define. 
Relative effectiveness of vinorelbine 
There are many trials of vinorelbine in NSCLC that could be
considered when appraising its efficacy. Probably the two most
relevant are the following. A large trial (n = 612) by Chevalier et al
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doi: 10.1054/ bjoc.2001.1890, available online at http://www.idealibrary.com on (1994) showed median survival to be 40 weeks for vinorelbine
plus cisplatin and 32 weeks for vindesine and cisplatin. Wozniak
et al (1998) in another large (n = 432) phase III study, reported
median survivals of 8 and 6 months for vinorelbine plus cisplatin
and cisplatin alone, respectively. Thus, on the basis of these two
large studies the survival benefit of adding vinorelbine to
cisplatin appears to be about 2 months. 
These two trials were high-quality randomized phase III trials
so any conclusion we drew from them (even if incorrect) could be
described as being based on alpha + evidence. Although a 2
months survival benefit is less than the 3 months that would auto-
matically qualify it as a B for clinical effectiveness, it is also more
than is required to qualify it as a C. It is in situations such as this
where the consensus meetings described in the paper are invalu-
able. Attendees felt that the QoL impact of vinorelbine plus
cisplatin were such as to merit a B rating. If treatments were rated
by the inflexible application of rules then there would be no need
for consensus meetings. 
The study Dr Botwood cites (Sandler et al, 2000) in support of
gemcitabine was only published in the Journal of Clinical
Oncology in January 2000, 3 months after the original submission
of our manuscript. 
Gemcitabine licence 
The original wording of the gemcitabine Summary of Product
Characteristics in NSCLC reads ‘for the palliative treatment of
adult patients with locally advanced or metastatic NSCLC’. This
has subsequently been modified to include an indication for first-
line use with cisplatin. The original wording says nothing about
line of treatment and is open to interpretation. We would interpret
it as meaning that gemcitabine monotherapy can be used in
NSCLC as first-line treatment or at any point in treatment where
the prescriber thinks fit. We would concede his point that an error
has crept in suggesting that the evidence for using gemcitabine
second-line is much weaker than Table 3. 
Endpoints 
Dr Botwood makes a useful point that there are multiple outcomes,
which can be assessed when appraising cancer treatments. Our own
recent discussions acknowledge this and if he wishes to promote
discussion on this matter we think this would be most interesting. 
Dr Jamie Ferguson 
Consultant in Public Health Medicine 
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Editor’s comment 
These letters raise a number of important issues for evaluating
cancer therapies. New drugs or new combinations are being tested
all the time and even in the time between writing and acceptance
of the paper by Ferguson et al, there were important new trials that
change the perspective on treatment of common cancers. At a time
when national programmes of evaluation, such as those of the
National Institute for Clinical Excellence (NICE), are increasingly
being applied to new cancer drugs, it is important that the limita-
tions of such analyses are recognized. 
(1) The analyses need to be continually updated in the light of
new data. 
(2) The most appropriate tools for evaluating palliative treatments
without significant survival benefit are not well established. 
It is also important that the outcomes of such analyses are not
applied too rigidly. In many instances the difference between
comparable treatments is small and side effects may vary. In these
circumstances, clinical judgement and patient choice may be
important features in deciding the most appropriate treatment. 
Robert Hawkins 
Clinical Editor British Journal of Cancer
E-mail: RHawkins@picr.man.ac.uk 
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